Type A Aortic Dissection After a Transcatheter Aortic Valve Replacement in a Prohibitive Surgical Risk Candidate

Abstract

TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) is the procedure of choice for patients with severe aortic stenosis (AS) and a prohibitive surgical risk, replacing surgical aortic valve replacement (SAVR).1 Although better patient selection, improved valve deployment systems, and increased operator experience have reduced the associated morbidity and mortality with TAVR, there is still a 6% to 8% incidence of major complications, which has been associated with a 2- to 3-fold increase in 30-day mortality.